Publications by authors named "Zi-lin Cui"
Intratumoural microorganism can affect the progression of hepatocellular carcinoma.
World J Gastrointest Oncol
October 2024
Background: Several recent studies have confirmed that intratumoural microorganisms can affect the occurrence and development of hepatocellular carcinoma (HCC); however, their role in tumor progression remains unclear. Hence, there is a need for further research on the role of intratumoural microorganisms in HCC.
Aim: To investigate the changes in intratumoural microorganisms in HCC and the effect of on HCC progression.
Risk of cardiovascular death in patients with hepatocellular carcinoma based on the Fine-Gray model.
World J Gastrointest Oncol
March 2024
Background: Hepatocellular carcinoma (HCC) is one of the most common types of cancers worldwide, ranking fifth among men and seventh among women, resulting in more than 7 million deaths annually. With the development of medical technology, the 5-year survival rate of HCC patients can be increased to 70%. However, HCC patients are often at increased risk of cardiovascular disease (CVD) death due to exposure to potentially cardiotoxic treatments compared with non-HCC patients.
View Article and Find Full Text PDFArticle Synopsis
- During cirrhosis, impaired liver function leads to reduced thrombopoietin (TPO) production and hypersplenism, which causes decreased platelet counts and an increased risk of bleeding.
- The study aimed to assess the effectiveness of recombinant human TPO (rhTPO) in treating low platelet counts (thrombocytopenia) in cirrhotic mice undergoing liver transplantation.
- Results showed that rhTPO treatment before and after surgery significantly improved platelet levels, while blocking TPO receptors worsened thrombocytopenia, indicating the crucial role of TPO in managing platelet counts in cirrhotic conditions.
Background: Regorafenib is a standard 2nd-line treatment for patients with advanced hepatocellular carcinoma (HCC), but the efficacy and safety of sequential therapy with sorafenib and regorafenib among advanced HCC patients in China is not clear.
Methods: This was a retrospective, two-center, cohort study of advanced HCC patients who received sequential therapy of sorafenib and regorafenib from October 2018 to April 2020 at 2 Chinese institutions. The patients were converted directly to regorafenib after failing to respond to sorafenib monotherapy.
Pre-treatment with FK506 reduces hepatic ischemia-reperfusion injury in rats.
Clin Res Hepatol Gastroenterol
April 2019
Aim: The study is aimed to investigate the protective effects and possible mechanism of tacrolimus (FK506) pre-treatment in hepatic ischemia-reperfusion injury in rats.
Methods: The rats were randomly assigned into four groups, which were S, IR, L and H group, and then all groups were subjected to 60min of 70% partial warm liver ischemia, except S group. Rats in the L and H group were pre-treated with two different doses FK506 at 60min before ischemia.
Objectives: In this study, we evaluated the effects of CXC chemokine receptor type 4 and stromal cell-derived factor 1 signaling in the progression of chronic allograft nephropathy in a rat model.
Materials And Methods: Experimental rats were divided into 3 groups: Lewis-to-Lewis isograft transplant (group A), Fisher 344 rat-to-Lewis allograft transplant with immunosuppressant cyclosporine (group B), and Fisher 344 rat-to-Lewis allograft transplant treated with cyclosporine and the CXC chemokine receptor type 4 antagonist AMD3100 (1 mg/kg/d) (group C). On day 90 after the operation, renal graft function, proteinuria, and histologic Banff score were measured.
Liver tumor boundaries identified intraoperatively using real-time indocyanine green fluorescence imaging.
J Cancer Res Clin Oncol
January 2017
Purpose: Clear delineation between tumors and normal tissues is ideal for real-time surgical navigation imaging. We investigated applying indocyanine green (ICG) fluorescence imaging navigation using an intraoperative administration method in liver resection.
Methods: Fifty patients who underwent liver resection were divided into two groups based on clinical situation and operative purpose.
Aim: To investigate the therapeutic effects and mechanisms of interleukin (IL)-22 in liver regeneration in mice with concanavalin A (ConA)-induced liver injury following 70% hepatectomy.
Methods: Mice were injected intravenously with ConA at 10 μg/g body weight 4 d before 70% hepatectomy to create a hepatitis model, and recombinant IL-22 was injected at 0.125 μg/g body weight 30 min prior to 70% hepatectomy to create a therapy model.
Background: Acute rejection is a major obstacle in patients with prolonged ischemia in deceased-donor renal transplantation. Chemokines and their receptors play a critical role in leukocyte trafficking, resulting in allograft rejection; therefore, the role of chemokine receptor CXCR3 in acute rejection induced by prolonged ischemia in rat kidney transplantation models was evaluated.
Methods: Syngeneic and allogeneic renal transplantations were performed.